Cargando…
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010121/ https://www.ncbi.nlm.nih.gov/pubmed/35441128 http://dx.doi.org/10.1097/HS9.0000000000000712 |
| _version_ | 1784687416439734272 |
|---|---|
| author | Dreyling, Martin Goy, Andre Hess, Georg Kahl, Brad S. Hernández-Rivas, José-Ángel Schuier, Natasha Qi, Keqin Deshpande, Sanjay Zhu, Angeline Parisi, Lori Wang, Michael L. |
| author_facet | Dreyling, Martin Goy, Andre Hess, Georg Kahl, Brad S. Hernández-Rivas, José-Ángel Schuier, Natasha Qi, Keqin Deshpande, Sanjay Zhu, Angeline Parisi, Lori Wang, Michael L. |
| author_sort | Dreyling, Martin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9010121 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90101212022-04-18 Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up Dreyling, Martin Goy, Andre Hess, Georg Kahl, Brad S. Hernández-Rivas, José-Ángel Schuier, Natasha Qi, Keqin Deshpande, Sanjay Zhu, Angeline Parisi, Lori Wang, Michael L. Hemasphere Letter Lippincott Williams & Wilkins 2022-04-13 /pmc/articles/PMC9010121/ /pubmed/35441128 http://dx.doi.org/10.1097/HS9.0000000000000712 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
| spellingShingle | Letter Dreyling, Martin Goy, Andre Hess, Georg Kahl, Brad S. Hernández-Rivas, José-Ángel Schuier, Natasha Qi, Keqin Deshpande, Sanjay Zhu, Angeline Parisi, Lori Wang, Michael L. Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up |
| title | Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up |
| title_full | Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up |
| title_fullStr | Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up |
| title_full_unstemmed | Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up |
| title_short | Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up |
| title_sort | long-term outcomes with ibrutinib treatment for patients with relapsed/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010121/ https://www.ncbi.nlm.nih.gov/pubmed/35441128 http://dx.doi.org/10.1097/HS9.0000000000000712 |
| work_keys_str_mv | AT dreylingmartin longtermoutcomeswithibrutinibtreatmentforpatientswithrelapsedrefractorymantlecelllymphomaapooledanalysisof3clinicaltrialswithnearly10yearsoffollowup AT goyandre longtermoutcomeswithibrutinibtreatmentforpatientswithrelapsedrefractorymantlecelllymphomaapooledanalysisof3clinicaltrialswithnearly10yearsoffollowup AT hessgeorg longtermoutcomeswithibrutinibtreatmentforpatientswithrelapsedrefractorymantlecelllymphomaapooledanalysisof3clinicaltrialswithnearly10yearsoffollowup AT kahlbrads longtermoutcomeswithibrutinibtreatmentforpatientswithrelapsedrefractorymantlecelllymphomaapooledanalysisof3clinicaltrialswithnearly10yearsoffollowup AT hernandezrivasjoseangel longtermoutcomeswithibrutinibtreatmentforpatientswithrelapsedrefractorymantlecelllymphomaapooledanalysisof3clinicaltrialswithnearly10yearsoffollowup AT schuiernatasha longtermoutcomeswithibrutinibtreatmentforpatientswithrelapsedrefractorymantlecelllymphomaapooledanalysisof3clinicaltrialswithnearly10yearsoffollowup AT qikeqin longtermoutcomeswithibrutinibtreatmentforpatientswithrelapsedrefractorymantlecelllymphomaapooledanalysisof3clinicaltrialswithnearly10yearsoffollowup AT deshpandesanjay longtermoutcomeswithibrutinibtreatmentforpatientswithrelapsedrefractorymantlecelllymphomaapooledanalysisof3clinicaltrialswithnearly10yearsoffollowup AT zhuangeline longtermoutcomeswithibrutinibtreatmentforpatientswithrelapsedrefractorymantlecelllymphomaapooledanalysisof3clinicaltrialswithnearly10yearsoffollowup AT parisilori longtermoutcomeswithibrutinibtreatmentforpatientswithrelapsedrefractorymantlecelllymphomaapooledanalysisof3clinicaltrialswithnearly10yearsoffollowup AT wangmichaell longtermoutcomeswithibrutinibtreatmentforpatientswithrelapsedrefractorymantlecelllymphomaapooledanalysisof3clinicaltrialswithnearly10yearsoffollowup |